Inhibition by SR 59119A of isoprenaline-, forskolin- and VIP-induced relaxation of human isolated bronchi.
In the human isolated bronchus (HIB) it has been shown that beta(3)-adrenoceptor stimulation fails to induce relaxation of airway smooth muscle. It has however been reported in human ventricular endomyocardial biopsies that beta(3)-adrenoceptor stimulation induced a marked negative inotropic effect which could be linked to Gi protein activation. The aims of this study were: (1) to determine in HIB (internal diameter 1-2 mm) whether the selective beta(3)-adrenoceptor agonist SR 59119A (N[7-methoxy-1,2,3, 4-tetrahydronaphthalen-(2R)methyl]-(2R)-2-hydroxy-2-(3-chloroph eny l)e thanamine hydrochloride) was able to inhibit adenylate-cyclase-mediated airway smooth muscle relaxation induced by isoprenaline, forskolin or vasoactive intestinal peptide (VIP) and (2) to investigate the role of the Gi protein in this interaction. SR 59119A (0.1 microM and 1 microM) induced a shift to the right of concentration response curve for isoprenaline (-0. 15+/-0.06 and -0.54+/-0.21 log unit, P<0.05 and P<0.01 respectively), forskolin (-0.12+/-0.02 and -0.30+/-0.05 log unit, P<0.001), and VIP (-0.42+/-0.12 log unit, P<0.01 with SR59119A 10(-6)M). The inhibitory effect of SR 59119A was (1) abolished by an incubation of HIB with pertussis toxin (1 microg/ml, during 15 h in Krebs-Henseleit solution, at 21 degrees C), which is known to inactivate the Gi protein and (2) increased after an incubation of HIB with the pro-inflammatory cytokine IL-1beta (10 ng/ml, during 15 h in Krebs-Henseleit solution, at 21 degrees C), which is known to up-regulate Gi protein expression. Our results suggest that the selective beta(3)-adrenoceptor agonist SR59119A might inhibit the cAMP-dependent relaxation of human isolated bronchus through Gi protein-mediated inhibition of adenylate cyclase.
Naline
E
E
Département de Pharmacologie, Faculté de Médecine Paris-Ouest, 15 Rue de Lécole de Médecine, Paris, France.
Bardou
M
M
Devillier
P
P
Molimard
M
M
Dumas
M
M
Chalon
P
P
Manara
L
L
Advenier
C
C
D000249:Adenosine Monophosphate / Q000378:metabolism; D037361:Adenylate Cyclase Toxin; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D001980:Bronchi / Q000187:drug effects* / Q000502:physiology; D005576:Colforsin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004983:Ethanolamines / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007375:Interleukin-1; D007545:Isoproterenol / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008875:Middle Aged; D037342:Pertussis Toxin; D011943:Receptors, Adrenergic, beta / Q000502:physiology*; D013764:Tetrahydronaphthalenes / Q000494:pharmacology*; D014660:Vasoactive Intestinal Peptide / Q000037:antagonists & inhibitors / Q000494:pharmacology; D010566:Virulence Factors, Bordetella
D037361:Adenylate Cyclase Toxin; D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D007375:Interleukin-1; D011943:Receptors, Adrenergic, beta; C114930:SR 59119A; D013764:Tetrahydronaphthalenes; D010566:Virulence Factors, Bordetella; D005576:Colforsin; D014660:Vasoactive Intestinal Peptide; D000249:Adenosine Monophosphate; D037342:Pertussis Toxin; D007545:Isoproterenol